Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7813MR)

This product GTTS-WQ7813MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7813MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1395MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ14444MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ11149MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ672MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ7519MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ12306MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ5045MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ4321MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW